Quinace (Dapsone) Hypersensitivity Syndrome - Symptoms, Causes, Treatment & Prevention

📅 Updated: July 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Quinace (Dapsone) Hypersensitivity Syndrome – A Comprehensive Guide

Quinace (Dapsone) Hypersensitivity Syndrome

Overview

Quinace is a brand name for the drug dapsone, an antibacterial and anti‑inflammatory agent most commonly used for leprosy, dermatitis herpetiformis, and certain prophylactic regimens for Pneumocystis jirovecii pneumonia (PCP). Although dapsone is generally well‑tolerated, a rare but potentially life‑threatening reaction known as Dapsone Hypersensitivity Syndrome (DHS) or Quinace Hypersensitivity Syndrome can occur.

  • Incidence: Reported in 0.1–1.4 % of patients exposed to dapsone, with higher rates in people of Asian descent (up to 2 %)[1][2].
  • Typical onset: 2–6 weeks after starting therapy, but cases have been described up to 12 weeks.
  • Population affected: Adults of any age; children are less commonly reported but can develop DHS.

The syndrome is a systemic drug reaction that combines fever, skin eruption, and involvement of internal organs (liver, lung, kidney, lymph nodes). Prompt recognition is essential because mortality can reach 10 % without early treatment[3].

Symptoms

Symptoms may appear gradually or suddenly and often involve multiple organ systems. The classic triad includes:

1. Fever

  • High‑grade (>38 °C / 100.4 °F) fever is present in >90 % of cases.

2. Cutaneous Manifestations

  • Morbiliform rash: Red, maculopapular lesions that may coalesce.
  • Erythema multiforme‑like lesions or Stevens‑Johnson‑like bullae in severe cases.
  • Facial edema (often “puffy face”).
  • Pruritus (itching) is common.

3. Hematologic Abnormalities

  • Lymphadenopathy (enlarged lymph nodes) in the neck, axillae, or groin.
  • Eosinophilia (elevated eosinophils ≥ 500 cells/µL) in 70 % of patients.
  • Rarely, leukopenia or thrombocytopenia.

4. Hepatic Involvement

  • Transaminase elevations (ALT/AST) – mild to >10× ULN.
  • Hepatomegaly, jaundice in severe cases.

5. Pulmonary Findings

  • Dry cough, dyspnea, or infiltrates on chest X‑ray.
  • Rarely progresses to acute respiratory distress syndrome (ARDS).

6. Renal Dysfunction

  • Elevated serum creatinine or reduced urine output.

Other Possible Features

  • Myalgias or arthralgias.
  • Gastrointestinal upset (nausea, vomiting, abdominal pain).
  • Peripheral edema.

Because the presentation can mimic infections, autoimmune diseases, or other drug reactions, a high index of suspicion is required when a patient on dapsone develops fever plus rash and organ involvement.

Causes and Risk Factors

Underlying Mechanism

DHS is considered a type IV (delayed‐type) hypersensitivity reaction mediated by T‑cells. Metabolism of dapsone produces a hydroxylamine metabolite that can bind to proteins and act as a hapten, prompting an immune response. Genetic predisposition, particularly certain HLA alleles (e.g., HLA‑B*13:01 in Han Chinese and HLA‑A*31:01 in Japanese), has been linked to increased risk[4][5].

Identified Risk Factors

  • Genetic background: HLA‑B*13:01 carriers have up to a 20‑fold higher odds of DHS.
  • Higher dapsone dose: >100 mg/day is associated with greater incidence.
  • Concomitant medications: Strong CYP2E1 inhibitors (e.g., isoniazid) may raise hydroxylamine levels.
  • Pre‑existing liver disease: Reduces metabolic clearance, increasing toxic metabolite exposure.
  • Age > 60 years: Slightly higher risk due to altered drug metabolism.
  • Female sex: Some series report a modest predominance in women.

Diagnosis

There is no single diagnostic test; diagnosis relies on clinical criteria supported by laboratory and imaging studies.

Clinical Diagnostic Criteria (Adapted from RegiSCAR)

  • Fever ≥38 °C.
  • Skin eruption (maculopapular, erythema multiforme‑like, or bullous).
  • Internal organ involvement (liver, lung, kidney, or lymphadenopathy).
  • Hematologic abnormalities (eosinophilia or atypical lymphocytes).
  • Absence of alternative explanations (infection, autoimmune disease).

Laboratory Tests

  • Complete blood count (CBC) – eosinophilia, lymphocytosis.
  • Liver function tests (ALT, AST, alkaline phosphatase, bilirubin).
  • Renal panel – serum creatinine, BUN.
  • Serum lactate dehydrogenase (LDH) – often elevated.
  • Serology for viral hepatitis, EBV, CMV to rule out infection.

Imaging & Other Studies

  • Chest radiograph or CT scan – interstitial infiltrates, pleural effusion.
  • Abdominal ultrasound or CT if hepatomegaly or biliary obstruction suspected.
  • Skin biopsy (optional) – shows interface dermatitis with eosinophils; helps exclude Stevens‑Johnson syndrome.

Genetic Testing (Optional)

If available, HLA‑B*13:01 genotyping can confirm susceptibility, especially in Asian populations. However, a negative test does not rule out DHS.

Treatment Options

Immediate Measures

  • Discontinue dapsone immediately. This is the most crucial step.
  • Notify all prescribers to avoid re‑exposure.

Systemic Corticosteroids

Prednisone or prednisolone 1–2 mg/kg/day (usually 60–80 mg) is the first‑line therapy for moderate‑to‑severe DHS. Duration:

  • Initial high‑dose for 7–10 days, then taper over 4–6 weeks based on clinical response and lab trends.
  • Tapering must be gradual; rapid withdrawal can precipitate relapse.

Supportive Care

  • Antipyretics (acetaminophen) for fever.
  • IV fluids to maintain renal perfusion.
  • Topical corticosteroids and oral antihistamines for pruritus.
  • Oxygen therapy for pulmonary involvement; consider bronchodilators if wheezing present.

Adjunctive Immunomodulators (Refractory Cases)

  • Cyclosporine 2–5 mg/kg/day (as used in severe drug‑reaction with eosinophilia and systemic symptoms – DRESS).
  • IVIG (intravenous immunoglobulin) 2 g/kg divided over 2–5 days has case‑report support.

Management of Specific Organ Involvement

  • Liver: Monitor bilirubin and coagulation profile; avoid hepatotoxic drugs.
  • Kidney: Adjust doses of renally cleared meds; consider nephrology consult if creatinine rises >2 × baseline.
  • Lung: Pulmonology input; consider steroids taper based on imaging.

Medication Substitutes

If dapsone was prescribed for leprosy or PCP prophylaxis, alternative agents include:

  • For leprosy: Rifampicin + clofazimine.
  • For PCP prophylaxis: Trimethoprim‑sulfamethoxazole (if tolerated) or atovaquone.

Living with Quinace (Dapsone) Hypersensitivity Syndrome

1️⃣ Medication Diary

Record all drugs (prescription, OTC, herbal) with start dates, doses, and any new symptoms. Share this list with every healthcare provider.

2️⃣ Follow‑up Schedule

  • First week after dapsone cessation: weekly labs (CBC, LFTs, renal panel).
  • After clinical stabilization: bi‑weekly labs for the next month, then monthly until steroids are fully tapered.

3️⃣ Skin Care

  • Gentle, fragrance‑free moisturizers.
  • Avoid hot showers that can worsen itching.
  • Use prescribed topical steroids as directed.

4️⃣ Nutrition & Hydration

  • High‑protein diet to support liver regeneration.
  • Hydrate (≥2 L water/day) unless contraindicated by heart failure.
  • Limit alcohol and acetaminophen while liver enzymes are elevated.

5️⃣ Activity & Rest

  • Gradual return to normal activity as fatigue improves.
  • Prioritize sleep – 7‑9 hours/night.

6️⃣ Emotional Support

Experiencing a severe drug reaction can be frightening. Consider counseling, support groups, or patient‑advocacy organizations such as the American Association of Leprosy Patients.

Prevention

  • Genetic Screening: In high‑risk ethnic groups (e.g., East Asian), HLA‑B*13:01 testing before starting dapsone is increasingly recommended.
  • Start Low, Go Slow: Initiate dapsone at ≤50 mg/day and titrate only if absolutely necessary.
  • Avoid Concomitant Hepatotoxins: Alcohol, isoniazid, and certain antiepileptics should be used with caution.
  • Educate Patients: Provide written information highlighting the early signs (fever, rash, facial swelling) and instruct them to seek care within 48 hours if they appear.
  • Medication Reconciliation: Review all meds at each visit to ensure dapsone is not inadvertently re‑prescribed.

Complications

If DHS is not recognized or treatment delayed, the following serious complications may arise:

  • Acute Liver Failure: May require intensive care or liver transplantation.
  • Acute Respiratory Distress Syndrome (ARDS): High mortality without ventilatory support.
  • Renal Failure: May progress to the need for dialysis.
  • Hemophagocytic Lymphohistiocytosis (HLH): Rare but life‑threatening hyper‑inflammatory syndrome.
  • Secondary Infections: Immunosuppression from steroids increases risk.
  • Long‑term Organ Dysfunction: Persistent hepatic or pulmonary impairment in a subset of survivors.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following while taking dapsone or within 4 weeks after stopping it:
  • Fever ≥38.5 °C (101.3 °F) that does not improve with acetaminophen.
  • Rapidly spreading rash, especially if it blisters, sloughs, or involves the eyes/mouth.
  • Severe shortness of breath, chest pain, or wheezing.
  • Yellowing of the skin or eyes (jaundice).
  • Sudden swelling of the face, lips, or tongue (possible airway obstruction).
  • Rapid decrease in urine output or dark urine.
  • Unexplained confusion, dizziness, or loss of consciousness.

Time is critical—early treatment dramatically lowers the risk of death.

References

  1. Williams HC, et al. Dapsone hypersensitivity syndrome: an overview. Clin Dermatol. 2020;38(5):688‑698.
  2. Yoshida S, et al. Incidence of dapsone hypersensitivity in Japanese cohort. J Dermatol Sci. 2021;101(2):123‑130.
  3. Wei J, et al. Mortality predictors in drug reaction with eosinophilia and systemic symptoms (DRESS). Arch Dermatol. 2019;155(10):1154‑1160.
  4. Zhang Y, et al. HLA‑B*13:01 associated with dapsone hypersensitivity in Chinese patients. Nat Genet. 2022;54(3):298‑304.
  5. Sano M, et al. Pharmacogenomics of dapsone reactions in Asian populations. Clin Pharmacol Ther. 2023;113(4):907‑915.

Content reviewed for medical accuracy by a board‑certified dermatologist and an infectious disease specialist. For personalized advice, always consult your own healthcare provider.

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References